In another study of 109 NSCLC patients, Mazzaschi et al. examined pre-treatment soluble PD-L1 (sPD-L1), circulating PD1+ CD8+ and NK cells as biomarkers in predicting ICI response. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.